Clinical trial
Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Retreatment Study of Sargramostim (Leukine®) in Patients With Active Crohn's Disease and Prior Treatment Response to Sargramostim
NCT00206713 is registered in ClinicalTrials.gov with Genzyme, a Sanofi Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Retreatment Study of Sargramostim (Leukine®) in Patients With Active Crohn's Disease and Prior Treatment Response to Sargramostim
- Lead sponsor
- Genzyme, a Sanofi Company
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- July 31, 2004
- Completion date
- October 31, 2006
- Enrollment
- 264 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.